Cipher Pharmaceuticals (TSE:CPH) Hits New 12-Month High at $9.17

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as C$9.17 and last traded at C$9.26, with a volume of 63001 shares traded. The stock had previously closed at C$8.77.

Analysts Set New Price Targets

Separately, Citigroup boosted their target price on Cipher Pharmaceuticals from C$4.75 to C$8.00 and gave the stock a “buy” rating in a research report on Wednesday, February 14th.

Cipher Pharmaceuticals Price Performance

The company has a 50-day simple moving average of C$6.75 and a 200-day simple moving average of C$5.70. The company has a market cap of C$217.14 million, a price-to-earnings ratio of 5.16 and a beta of 0.97. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.67 and a current ratio of 4.07.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last announced its quarterly earnings results on Thursday, March 14th. The company reported C$0.41 EPS for the quarter, topping the consensus estimate of C$0.15 by C$0.26. The business had revenue of C$6.70 million for the quarter, compared to analyst estimates of C$7.31 million. Cipher Pharmaceuticals had a return on equity of 53.13% and a net margin of 153.23%. As a group, research analysts predict that Cipher Pharmaceuticals Inc. will post 0.5946622 earnings per share for the current year.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.